Tin tức & Cập nhật
Lọc theo Chuyên ngành:

How viable is a self-administered injection in adults with HIV?
A substudy of the phase III FLAIR study has found comparable efficacy and pharmacokinetics for cabotegravir (CAB) plus rilpivirine (RPV) via subcutaneous (SC) administration relative to those via intramuscular (IM) gluteal injections among virally suppressed individuals living with HIV-1.
How viable is a self-administered injection in adults with HIV?
05 Aug 2024
Extended TB surveillance needed for specific IGRA-negative individuals
Certain individuals initially testing negative for tuberculosis (TB) by interferon-gamma release assay (IGRA) may later contract the infection and therefore require extended follow-up due to increased risk, as reported in a study from Singapore.
Extended TB surveillance needed for specific IGRA-negative individuals
30 Jul 2024
Can mouthwash cut COVID-19 salivary viral load?
In COVID-19 patients who had mild or no symptoms, the use of 0.05% cetylpyridinium chloride (CPC) and 0.01% on-demand aqueous chlorine dioxide (ACD) mouthwashes did not lead to a reduction in SARS-CoV-2 salivary viral load.
Can mouthwash cut COVID-19 salivary viral load?
23 Jul 2024
Acute benign myositis may occur in kids with flu infection
Children with influenza A virus infection are susceptible to acute benign myositis (ABM), with most patients showing clinical characteristics consistent with postfebrile myalgia, reports a study.
Acute benign myositis may occur in kids with flu infection
21 Jul 2024
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
Evaluation and treatment rates of patients with chronic hepatitis B (CHB) remain poor worldwide and differ by sex and race or ethnicity, reports a real-world study.
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
19 Jul 2024
Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease
In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).